Brookline Capital Downgrades Outlook Therapeutics to Hold
Portfolio Pulse from richadhand@benzinga.com
Brookline Capital analyst Kumaraguru Raja has downgraded Outlook Therapeutics (NASDAQ:OTLK) from Buy to Hold.

August 30, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Outlook Therapeutics has been downgraded from Buy to Hold by Brookline Capital, which could potentially impact the stock's performance.
Analyst ratings often influence investor sentiment and can impact a stock's price. A downgrade from Buy to Hold suggests that the analyst sees less upside potential, which could lead to a decrease in demand for the stock and potentially lower prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100